1. Home
  2. ACB vs FENC Comparison

ACB vs FENC Comparison

Compare ACB & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aurora Cannabis Inc.

ACB

Aurora Cannabis Inc.

HOLD

Current Price

$5.17

Market Cap

260.2M

Sector

Health Care

ML Signal

HOLD

Logo Fennec Pharmaceuticals Inc.

FENC

Fennec Pharmaceuticals Inc.

HOLD

Current Price

$7.76

Market Cap

258.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACB
FENC
Founded
2013
1996
Country
Canada
United States
Employees
N/A
N/A
Industry
Pharmaceuticals and Biotechnology
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
260.2M
258.5M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
ACB
FENC
Price
$5.17
$7.76
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
1.3M
219.0K
Earning Date
02-04-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$263,570,704.00
$38,790,000.00
Revenue This Year
$11.82
N/A
Revenue Next Year
$8.58
$75.22
P/E Ratio
N/A
N/A
Revenue Growth
23.89
N/A
52 Week Low
$3.42
$4.68
52 Week High
$6.91
$9.92

Technical Indicators

Market Signals
Indicator
ACB
FENC
Relative Strength Index (RSI) 61.47 47.22
Support Level $4.43 $7.35
Resistance Level $5.51 $7.74
Average True Range (ATR) 0.21 0.35
MACD 0.10 0.02
Stochastic Oscillator 69.62 43.33

Price Performance

Historical Comparison
ACB
FENC

About ACB Aurora Cannabis Inc.

Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.

About FENC Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Share on Social Networks: